Education
About Us
Working with TipRanks
Follow Us
Vaxart Inc (VXRT)
NASDAQ:VXRT
VXRT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $1.41
Previous CloseN/A
Volume1.40M
Average Volume (3M)1.83M
Market Cap
$107.35M
Enterprise Value$157.47M
Total Cash (Recent Filing)$11.46M
Total Debt (Recent Filing)$3.61M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 07, 2025EPS Estimate
-0.1Last Dividend Ex-Date
Nov 09, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-0.41
Shares Outstanding227,479,810
10 Day Avg. Volume3,045,414
30 Day Avg. Volume1,826,125
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.40
Price to Cash Flow (P/CF)-6.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.59
Enterprise Value/Ebitda-2.48
Forecast
1Y Price Target
$4.00Price Target Upside751.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Vaxart News
PremiumCompany Announcements
Vaxart Announces Board Changes with New Appointment
---
Bulls Say, Bears Say
Bulls Say
COVID-19 Vaccine DevelopmentVaxart advances with $453M BARDA-backed COVID-19 vaccine, poised to lead in mucosal immunity.
Regulatory ProgressManagement is in ongoing active discussions with the FDA, highlighted by a recent Type C meeting, to clarify potential late-stage development, which could expedite the path to market.
Bears Say
Investor PerceptionInvestor perception of the norovirus opportunity has considerable room for improvement given the significant disease burden and the lack of approved or late-stage programs.
---
Ownership Overview
1.04% Insiders
5.34% Mutual Funds
5.90% Other Institutional Investors
83.28% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VXRT FAQ
What was Vaxart Inc’s price range in the past 12 months?
Vaxart Inc lowest stock price was $0.45 and its highest was $1.41 in the past 12 months.
What is Vaxart Inc’s market cap?
Vaxart Inc’s market cap is $107.35M.
When is Vaxart Inc’s upcoming earnings report date?
Vaxart Inc’s upcoming earnings report date is May 07, 2025 which is in 59 days.
How were Vaxart Inc’s earnings last quarter?
Currently, no data Available
Is Vaxart Inc overvalued?
According to Wall Street analysts Vaxart Inc’s price is currently Undervalued.
Does Vaxart Inc pay dividends?
Vaxart Inc pays a Notavailable dividend of $12.188 which represents an annual dividend yield of N/A. See more information on Vaxart Inc dividends here
What is Vaxart Inc’s EPS estimate?
Vaxart Inc’s EPS estimate is -0.1.
How many shares outstanding does Vaxart Inc have?
Vaxart Inc has 227,479,810 shares outstanding.
What happened to Vaxart Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Vaxart Inc?
Currently, no hedge funds are holding shares in VXRT
---
Vaxart Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (751.06% Upside)
$4.00 (751.06% Upside)
Hedge Fund Trend
Increased
By 32.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.74%
12-Months-Change
Fundamentals
Return on Equity
-103.37%
Trailing 12-Months
Asset Growth
57.77%
Trailing 12-Months
Company Description
Vaxart Inc
Vaxart, Inc. is a biotechnology company that specializes in the development of oral recombinant vaccines based on its proprietary oral vaccine platform. The company is focused on creating vaccines that can be administered by tablet rather than by injection, aiming to make vaccination more accessible and easier to distribute. Vaxart operates within the pharmaceutical and biotechnology sectors, with its core products targeting infectious diseases and viral pathogens.
---
VXRT Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in the company's COVID-19 oral vaccine program with strong funding and partnership with BARDA, along with notable revenue growth. However, challenges remain in the norovirus program with the need for additional data as requested by the FDA. Overall, the positive developments in the COVID-19 and HPV programs, alongside revenue growth, present an optimistic outlook.Read More>---
VXRT Stock 12 Month Forecast
Average Price Target
$4.00
▲(751.06% Upside)
Technical Analysis
Best Analysts Covering VXRT
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-31.90%
reiterated a buy rating 4 months ago
Copying Mayank Mamtani's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -31.90% per trade.
---